Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) experienced a significant decrease in short interest during the month of May. As of May 31st, there were 60,600 shares sold short, a 16.9% decrease from the total on May 15th. This represents approximately 1.0% of the company’s shares being sold short. With an average daily trading volume of 544,300 shares, the short-interest ratio is currently 0.1 days.
The stock of Nexalin Technology opened at $0.90 on Friday, with a one-year low of $0.25 and a one-year high of $3.40. The company has a market capitalization of $6.69 million, a PE ratio of -1.36, and a beta of 5.13. The fifty-day moving average is $1.31, while the 200-day moving average is $0.80.
Nexalin Technology (NASDAQ:NXL – Get Free Report) recently reported its earnings results on Wednesday, March 27th. The company disclosed earnings per share (EPS) of ($0.10) for the quarter with revenue of $0.02 million. The company had a negative return on equity of 154.84% and a negative net margin of 3,088.12%.
Nexalin Technology, Inc. is a medical device company that designs and develops neurostimulation products for the treatment of mental health issues in the United States and China. The company is currently working on Generation 2 and Generation 3 products, which are in clinical trials for the treatment of substance abuse related to opiate, cocaine, alcohol abuse, Alzheimer’s disease, and dementia.